Hydralazine-Induced ANCA-Positive Pauci-immune Glomerulonephritis: A Case Report and Literature Review

Figures & data

Figure 1.  (a) Hematoxylin and eosin stain. Segmental endocapillary cellular proliferation (black arrow) and foci of tuft necrosis (white arrow). (b) Immunofluorescent microscopy. Focal glomerular C3 staining is evident in the mesangium.

Table 1  Hydralazine-associated ANCA-positive pauci-immune glomerulonephritis

	Almroth et al. (1992)	Cambridge et al. (1994)	Short & Lockwood(1995)	Choiet al. (2000)
Number of patients	17	4	10	10
Age range (years)	55–77	11–79	55–76	45–81
Hydralazine dose range (mg/day)	50–200	> 100	50–150	75–200
Duration of drug exposure (months)	25–168	> 24	36–156	12–63
Patients with kidney involvement	17	4	10	9
Patients with lung involvement	5	NR	2	5
Confirmed pauci-immune GN	NR	2	7	5
ANCA-positive	5	+	10	10
MPO-positive	14	+	10	10
Anti-histone-positive	NR	NR	NR	NR

Abbreviations: +, present; NR, not reported; GN, glomerulonephritis; ANCA, anti-neutrophil cytoplasmic antibodies; MPO, myeloperoxidase antibodies.